Around the world an increasing number of hospitals, physicians, nurses, therapists and homecare providers are choosing our medical devices to assist with the treatment of their patients.
Read more
Fisher & Paykel Healthcare Corporation Limited announced today that it has updated its revenue and earnings guidance for the financial year ending 31 March 2024.
Fisher & Paykel Healthcare Corporation Limited announced today that 27% revenue growth from its obstructive sleep apnea (OSA) product group contributed to record trading revenue of NZ$349.2 million for the year ended 31 March 2007.
Fisher & Paykel Healthcare Corporation Limited announced today that continuing strong volume growth in its obstructive sleep apnea (OSA), respiratory and acute care products contributed to operating revenue of NZ$172.5 million or US$127.7 million for six months en...
Fisher & Paykel Healthcare Corporation Limited today announced record net profit after tax of NZ$48.9 million for the half year, an increase of 10% over the first half last year.
Fisher & Paykel Healthcare Corporation Limited announced today that continuing strong growth in sales of its respiratory, acute care and obstructive sleep apnea (OSA) products contributed to record operating revenue of NZ$357.9 million or US$271.5 million for the year ended 31...
Fisher & Paykel Healthcare Corporation Limited announced today that it has updated its revenue and earnings guidance for the financial year ended 31 March 2020.
Find clinical evidence and practice guidelines for delivering nasal high flow (aka HFNC) therapy.
The heating and humidifying of respiratory gases is crucial for intubated patients. Learn about humidification devices, including active and passive.
Featuring under nose NIV masks (F&P Visairo) and full face NIV masks - (F&P Nivairo), with vented and non-vented options to suit your hospital NIV mask needs.
Establish effective spontaneous breathing or assist ventilation of the lungs
Respiratory support that replaces spontaneous breathing
Noninvasive respiratory support that provides a continuous distending pressure
Noninvasive respiratory support that delivers high flows of blended air and oxygen
Designed to work in harmony with the way patients naturally breathe while they sleep
F&P SleepStyle - designed to strike the balance between comfort and effective treatment
The AIRVO 2 family enables the transition of Optiflow therapy across critical, non-critical areas of the hospital and into the home.
Humidification for patients using a mask at home
Humidification for patients with a tracheostomy at home
Our newest Airvo features an integrated battery, high-pressure oxygen input and a broader flow range.
Optiflow nasal high flow therapy explained, what is it and how does it work?
F&P Solo™ Nasal is the world’s first AutoFit™ mask. It simplifies setup like no other, using AutoLock™ technology - stretch to fit, touch to adjust.
Airvo, F&P 950 and F&P 850 – this trio of humidification and respiratory support devices facilitate multiple respiratory therapies across the hospital
Join our global team. View and apply for jobs with us.
Get in touch with our team, find a distributor or send an enquire.
We value your privacy. Our websites and applications use cookies to function properly and securely.